Caribou Biosciences
immunotherapy, allo-CAR, NHL, MM
Caribou Biosciences
Berkeley, CA
United States
TAP Partner
Caribou is a clinical-stage biotechnology company, co-founded by CRISPR pioneer and Nobel Prize winner Jennifer Doudna, Ph.D., using next-generation CRISPR genome-editing technology to develop “off-the-shelf” (allogeneic) CAR therapies for hard-to-treat blood cancers.
Program Name(s)
Therapy Acceleration Program
Project Title
Leslie Crews, PhD
San Diego, CA
United States
University of California, San Diego
Dr. Leslie Crews is an Assistant Professor of Medicine at UCSD with a passion for stem cell biology and translational cancer research. She received her bachelor’s degree from UCLA and a PhD in Molecular Pathology from UCSD. During her postdoctoral training in leukemia and myeloma research, Dr. Crews and her collaborators discovered that the interferon-responsive RNA editing gene ADAR1 is hyper-activated in myeloma and that this molecule promotes disease progression and drug resistance by activating stem cell regulatory pathways. Since starting her independent laboratory in 2017 as a member of the Division of Regenerative Medicine and the Moores Cancer Center, the primary focus of the Crews Laboratory has been on multiple myeloma translational research. Her ongoing work aims to delve deeper into the molecular mechanisms of myeloma initiation and progression, with the goal of identifying novel, more selective therapies to treat individuals with this incurable cancer.
Program Name(s)
Career Development Program